TRDA Stock Analysis: Buy, Sell, or Hold?
TRDA - Entrada Therapeutics, Inc. Common Stock
$10.82
-0.97 (-8.23%)
▼
5d:
-2.96%
30d:
+3.05%
90d:
+59.59%
BUY
MODERATE Confidence
Analysis Updated: Feb 4, 2026 12:00 AM ET
Earnings: Feb 26, 2026
21d
Get Alerted When TRDA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: TRDA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: TRDA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: TRDA is currently trading at $10.82, which is considered fair relative to its 30-day fair value range of $10.23 to $11.40.
Technical Outlook: Technically, TRDA is in a strong uptrend. The price is currently testing key support at $10.52. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $18.00 (+52.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TRDA is in a strong uptrend. The price is currently testing key support at $10.52. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $18.00 (+52.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$10.23 -
$11.40
Company Quality Score
50/100
(HOLD)
Options IV Signal
42th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
69.6%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Options fairly priced (IV 42th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.2%)
- BULLISH: Trading 52.7% below Wall St target ($18.00)
Fair Price Analysis
30-Day Fair Range
$10.23 -
$11.40
Current vs Fair Value
FAIR
Expected Move (7 Days)
±$1.77
(16.3%)
Support & Resistance Levels
Support Level
$10.52
Resistance Level
$12.18
Current Trend
Strong Uptrend
Technical data as of
Feb 4, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.87
Wall Street Target
$18.00
(+52.7%)
Revenue Growth (YoY)
-91.8%
Profit Margin
-168.2%
Last updated: February 04, 2026 3:49 PM ET
Data refreshes hourly during market hours. Next update: 4:49 PM
Data refreshes hourly during market hours. Next update: 4:49 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TRDA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$213 | 61 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$56 | 57 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$64 | 57 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$102 | 60 HOLD |
|
ARVN
Arvinas Inc |
BUY
21 analysts |
$13 | 59 HOLD |